Literature DB >> 25109724

A study of Mycobacterium tuberculosis genotypic diversity & drug resistance mutations in Varanasi, north India.

Anamika Gupta, Savita Kulkarni, Nalin Rastogi, Shampa Anupurba1.   

Abstract

BACKGROUND &
OBJECTIVES: One-fifth of the world's new tuberculosis (TB) cases and two-thirds of cases in the South East Asian region occur in India. Molecular typing of Mycobacterium tuberculosis isolates has greatly facilitated to understand the transmission of TB. This study was aimed to investigate the molecular epidemiology of M. tuberculosis genotypes in Varanasi, north India, and their association with clinical presentation among patients with pulmonary TB.
METHODS: M. tuberculosis isolates from 104 TB patients attending a tertiary referral hospital of north India were screened for susceptibility to isoniazid (INH), rifampicin (RIF), ethambutol (EMB) and streptomycin (STR) by proportion method and multiplex-allele-specific-polymerase chain reaction (MAS-PCR). These were genotyped by spoligotyping. The spoligotype patterns were compared with those in the international SITVIT2 spoligotyping database.
RESULTS: Eighty three of 104 isolates were distributed in 38 SITs, of which SIT3366 was newly created within the present study. The mass of ongoing transmission with MDR-TB isolates in Varanasi, northern India, was linked to Beijing genotype followed by the CAS1_Delhi lineage. HIV-seropositive patients had a significantly higher proportion of clustered isolates than HIV-seronegative patients and compared with the wild type(wt) isolates, the isolates with katG315Thr mutation were considerably more likely to be clustered. INTERPRETATION &
CONCLUSIONS: This study gives an insight into the M. tuberculosis genetic biodiversity in Varanasi, north India, the predominant spoligotypes and their impact on disease transmission. In this region of north India, TB is caused by a wide diversity of spoligotypes with predominance of four genotype lineages: Beijing, CAS, EAI and T. The Beijing genotype was the most frequent single spoligotype and strongly associated with multi drug resistant (MDR)-TB isolates. These findings may have important implications for control and prevention of TB in north India.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25109724      PMCID: PMC4165002     

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


India accounts for one fifth of the world's new tuberculosis (TB) cases and two-thirds of cases in the South East Asia1. Regardless of the efforts to control TB, the disease burden of human TB is still a very serious and widespread public health problem particularly in developing countries. This situation is worsened by the appearance of multidrug-resistant (MDR), extensively drug resistant (XDR) strains of Mycobacterium tuberculosis and a high incidence of human immunodeficiency virus (HIV)/TB co-infection2. Molecular techniques in the TB field have provided new ways to study dissemination dynamics and evolutionary genetics of the pathogen, with a direct impact on TB control actions3. Spoligotyping is the second most widely used method for M. tuberculosis complex genotype after insertion sequence 6110 (IS6110)-based fingerprinting4. Spoligotyping in combination with mycobacterial interspersed repetitive units-variable-number of tandem DNA repeats (MIRU-VNTR) has been used to replace IS6110-restriction fragment length polymorphisms (RFLP) typing. The IS6110-RFLP method has been considered the gold standard for genotyping M. tuberculosis7, however, this is an expensive, laborious and extensive method that requires weeks for culturing and specific software to analyse the RFLP band patterns. Moreover, this method is not applicable to isolates having either too low or zero IS6110 copy number5. Spoligotyping is based on a polymorphism in the chromosomal direct repeat (DR) locus3 and has been applied to the characterization of the M. tuberculosis complex. It is internationally accepted as a rapid, first line discriminatory test and the gold standard for the identification of Beijing strains of M. tuberculosis67. The spoligotyping method was also the basis for making of the largest genotype database for M. tuberculosis, containing a global distribution and phylogenetic analysis for worldwide spoligotypes6. A better understanding of drug-resistant TB epidemiology is essential to develop evidence-based control strategies for MDR-TB. Drug-resistance is associated with a number of factors including poor adherence to anti-TB treatment8. MDR-TB is a result of the step-wise accumulation of mutations in drug-resistance conferring genes. Previously, drug-resistant M. tuberculosis strains were thought to be less infectious and less likely to cause disease when compared to their drug-susceptible counterparts9. However, recent studies have shown that these are able to transmit and cause disease as often as drug-susceptible organisms10. Further, the prevalence of different drug resistant clones of M. tuberculosis varies from one area to another and studies in different geographical settings are necessary to understand the epidemiology of disease11. This study was undertaken to provide with an insight into the M. tuberculosis genotypic diversity and drug resistance mutations in Varanasi, north India. We also compared our data on a global scale to present an in-depth analysis of prevailing M. tuberculosis clones to understand their probable transmission dynamics.

Material & Methods

The study was conducted at the Department of Microbiology, Institute of Medical Sciences, Banaras Hindu University (BHU) and Sir SundarLal (SS) Hospital, a tertiary-care hospital of BHU. Sputum specimens were collected during the period of January 2008 to January 2010, from clinically suspected pulmonary TB patients, from Varanasi and adjoining districts of Uttar Pradesh, attending various OPDs of SS Hospital, BHU, Varanasi. Culture and drug susceptibility testing (DST) of M. tuberculosis was done at Department of Microbiology, Institute of Medical Sciences, Banaras Hindu University (BHU) while spoligotyping was done at the Laboratory Nuclear Medicine Section, Isotope Group, Bhabha Atomic Research Centre, Mumbai, India. Specimens/mycobacterial isolates/phenotypic drug susceptibility testing: One hundred four clinical isolates of M. tuberculosis were recovered from sputum specimens from patients diagnosed with pulmonary TB on the basis of clinical symptoms, chest X-ray, and bacteriological examination. Demographic and epidemiological data were obtained on direct counselling with patients and from the medical records. Isolated cultures were identified by certain biochemical tests, such as heat-stable catalase, niacin accumulation, and susceptibility to p-nitro benzoic acid (PNB) followed by the amplification of a 523-bp DNA fragment specific for the IS6110 gene1213 present in all isolates. For this purpose, bacterial DNA was extracted by using the protocol of van Embden et al5 with slight modifications. Identified M. tuberculosis isolates were subjected to indirect DST according to the gold standard proportion method (PM) with the recommended critical concentrations of 40 μg/ml for rifampicin (RIF), 0.2 μg/ml for isoniazid (INH), 2 μg/ml for ethambutal (EMB) and 4 μg/ml for streptomycin (STR)1415. H37Rv (ATCC 27294) and a known MDR strain were used as negative and positive controls, respectively. Among the first line anti TB drugs pyrazinamide susceptibility testing was not done. Overall, 47 pan susceptible, 51 MDR and six other M. tuberculosis isolates (resistant to one or more first line anti-TB drugs) to see the association of prevailing drug-resistance with different lineages of M. tuberculosis. The study protocol was approved by the ethical committee of the Institute. HIV testing: Three rapid HIV test kits (initial screening by comb AIDS, if the test was reactive then Pareekshak Triline card and AIDSCAN Trispot test were performed) based on different antigens/principles were used to test the HIV status of patients according to NACO (National AIDS Control Organization) guidelines16. Multiplex allele-specific (MAS)-PCR assay for detection of RIF, INH and EMB resistance determinants: A two-step MAS-PCR assay was performed to detect mutations at rpoB codons (516, 526 and 531), katG codon 315 and embB codon 306171819. Two outer (forward & reverse) and three inner forward primers were used for three MAS-PCRs targeting three different codons of the rpoB gene while two outer and one inner reverse primers were used for katG315 MAS PCR and two outer and two inner primers were used for embB306 MAS PCR171819. Spoligotyping: Spoligotyping was performed (n=104) according to the standard method of Kamerbeek et al3. M. tuberculosis H37Rv and deionized autoclaved water were used as positive and negative controls in each experiment. The results were documented in the form of a binary code. Comparison of spoligotypes with an updated database: Spoligotypes in binary format were entered in the SITVIT2 database (Pasteur Institute of Guadeloupe, France), which is an updated version of the previously released SpolDB4 database6. At the time of the present study, SITVIT2 contained more than 3000 SITs (Spoligotype International Type) with global genotyping information on about 75,000 M. tuberculosis clinical isolates from 160 countries of origin. In this database, SIT designates spoligotypes shared by two or more patient isolates, as opposed to “orphan” which designates patterns reported for a single isolate. Major phylogenetic clades were assigned according to signatures provided in SpolDB4, which defined 62 genetic lineages/sub-lineages6. Statistical analysis: Descriptive analyses were performed using SPSS 15.0 (SPSS, Chicago, IL, USA). Binary logistic regression model was used for univariate and multivariate analyses to qualify and quantify the difference in clustering proportion between groups of subjects with different socio-demographic and clinical characteristics. The adjusted odds ratio (OR) and 95 per cent confidence interval (CI) were calculated by adjusting for the possible confounders (age and sex). Statistical significance was defined as P value of 0.05 or less. A cluster of M. tuberculosis isolates was defined as two or more isolates with identical spoligotyping patterns. A cluster of patients was defined as two or more patients with identical isolates. The geographical distribution of the clusters was assessed on the basis of the place of residence of the patients.

Results

In this study, a total of 104 isolates including drug susceptible and drug resistant both from the spectrum specimens collected from pulmonary TB patients were included. These were from 39 females (6 to 70 yr) and 65 males (16 to 75 yr). Further, 89 (85.58%) of these were HIV seronegative and 15 (14.42%) were HIV seropositive patients. Of all isolates, 47 (45.19%) were susceptible to all four first line drugs i.e., INH and RIF, STR and EMB while 57 (54.81) were resistant to one of these drugs. Of the 57 any drug resistant isolates, 55 (96.49%), 52 (91.23%), 41 (71.93%), 45 (78.95%) and 51 (89.47%) were INH, RIF, STR, EMB and multidrug resistant TB isolates, respectively. New and retreated cases were 56 (53.85%) and 48 (46.15%), respectively. Among 57 any drug resistant cases, 21 (36.84%) and 36 (63.12%) were primary and acquired drug resistant cases, respectively. Comparison of the spoligotypes with those in the international database: Comparison with the SITVIT2 database showed that 21 patterns (1 isolate per pattern) were not reported earlier to the database; these were classified as orphans (Table I), and corresponded to CAS1_DELHI (n=7), EAI5 (n=4), Manu 2 (n=3), Manu 1 (n=2), EAI3-IND (n=2), EAI4-VNM (n=1) families, respectively. The remaining two orphan isolates corresponded to an unknown pattern in one case, and an ambiguous pattern with a mixed LAM/T profile in another case. The remaining 83 isolates were distributed in 38 shared types or SITs (Table II). Twenty six (31.33%) isolates presented unique SITs, remaining 57 were clustered in 12 groups of 2 to 21 isolates each. SIT1 (Beijing clade) represented 20.39 per cent of all isolates, followed in predominance by SIT26 and SIT954 (CAS1_DELHI) which constituted 6.8 and 4.85 per cent of all isolates. Of the 38 SITs, 37 were matched to a pre-existing shared type in the database, whereas one SIT (SIT3366, n=3) was newly created within the study. Among the 26 isolates which were of unique SITs, seven (SIT24, 429, 794, 1327, 1346, 599, 2392), seven (SIT346, 380, 474, 591, 1373, 1390, 2457), five (SIT31, 358, 1129, 1267, 1163), two (SIT250, 621), two (SIT54, 1634) and one (SIT137) corresponded to CAS, EAI, T, Beijing, Manu and X family lineages while two (SIT27, 560) were of unknown origin.
Table I

Orphan isolates (n=21) and corresponding spoligotyping defined lineages/sublineages found among a total of 104 M. tuberculosis isolates from patients residing in Varanasi, north India

Table II

Description of 38 shared-types (n=83 isolates) and corresponding spoligotyping defined lineages/sublineages starting from a total of 104 M. tuberculosis isolates from patients residing in Varanasi, north India

Orphan isolates (n=21) and corresponding spoligotyping defined lineages/sublineages found among a total of 104 M. tuberculosis isolates from patients residing in Varanasi, north India Description of 38 shared-types (n=83 isolates) and corresponding spoligotyping defined lineages/sublineages starting from a total of 104 M. tuberculosis isolates from patients residing in Varanasi, north India Characteristics of the predominant spoligotypes in our study (patterns shared by two or more isolates) and their worldwide distribution in the SITVIT2 database (Table III) showed that a total of seven SITs predominated (representing 47/104 isolates, or 45.19% of all isolates); and corresponded to the following (in decreasing order): SIT1-Beijing (n = 21, 20.39%), SIT26-CAS1_DELHI (n = 7, 6.8%), SIT954- CAS1_DELHI (n = 5, 4.85%), SIT4-EAI3_IND (n = 4, 3.88%), SIT53 (n=4, 3.88%), SIT288-CAS2 (n = 3, 2.91%) and SIT3366-EAI3_IND (n = 3, 2.91%). Most of the spoligotypes (except SIT1 that predominated in East/South-East Asia, SIT53 in North/South America, and Europe, and SIT3366 that was newly described in our study) were simultaneously predominant in South Asia and North America. Note that 22.04, 20.33, 26.09 and 27.27 per cent of all cases with, respectively, SIT11, 26, 288 and 954 in the SITVIT2 database were reported from North America (22.04, 20.33, 26.09 and 27.27% from the United States, respectively). The isolates belonging to these four predominant lineages in the SITVIT2 database were also frequently reported from South Asia (43.33, 44.48, 51.09, and 63.64%, respectively, for SIT11, SIT26, SIT288, SIT954; and 35.93, 22.38, 43.48, and 54.55% being from India). Regarding SIT1, 34.52 per cent of cases with this pattern in SITVIT2 were reported from East-Asia, 21.18 per cent from North America, but only 3.85 per cent from South Asia. The third highest proportion of predominant spoligotypes was from Western Europe. The mean age of the patients’ harbouring predominant spoligotypes ranged from 22.25-36.36 years.
Table III

Description of major M. tuberculosis clusters in Varanasi (containing 3 or more isolates in our study), and their worldwide distribution in the SITVIT2 database

Description of major M. tuberculosis clusters in Varanasi (containing 3 or more isolates in our study), and their worldwide distribution in the SITVIT2 database Distribution of predominant spoligotypes by gender, age, HIV status and DST: Almost all SITs were more prevalent in men, except SIT53, being isolated from the patients in their productive age (mean age, 27.47-36.33 yr). SIT53 was more prevalent than all other spoligotypes in women, being isolated from the patients with the age ranges from 14-20 yr (mean age, 16.33 yr) (Table III). SIT1/Beijing genotype was highly prevalent in the multidrug-resistant as well as HIV seropositive groups (13/21 isolates were MDR, four of these being isolated from HIV seropositive patients), followed by the CAS1_DELHI lineage (SIT26 and SIT654) in 6/12MDR isolates (Table III). Association of clustered spoligotypes with clinical, epidemiological features of patients and phenotypic, genotypic DST: Binary logistic regression was applied to analyze the “clustering” of M. tuberculosis isolates in association with patients’ demographics, clinical profiles and the bacteriologic features (Table IV). Smear-negative TB patients had a significantly higher proportion of clustered isolates than smear-positive patients (77.27 vs. 48.78%; adjusted OR, 0.248; P, 0.015; 95%CI, 0.080-0.765), as well as in the HIV seropositive patients in comparison to HIV seronegative patients (80.0 vs.50.56%; adjusted OR, 3.943; P, 0.045; 95%CI, 1.031-15.077). However, there were no significant association between clustered M. tuberculosis isolates and age (mean ± SD, 31.47 ±13.9), sex, treatment history and radiological findings of the patients (Table IV).
Table IV

Association of clustered M. tuberculosis isolates with clinical, epidemiological characteristics of patients and different drugresistant pattern and genetic mutations* (n=104)

Association of clustered M. tuberculosis isolates with clinical, epidemiological characteristics of patients and different drugresistant pattern and genetic mutations* (n=104) Further, drug resistant/MDR-TB and acquired drug resistant/primary drug resistant isolates were clustered in almost same proportion compared to total genotyped isolates. Compared with wild type (wt) isolates, the isolates with the katG315Thr mutation were more likely to be clustered (60.0 vs. 20.0%) however, the proportion was not significant. Further, among RIF and EMB resistant isolates, rpoB516Leu, rpoB526Arg, rpoB531Leu and embB306Val, embB306Ile alleles, respectively were not associated with clustering (Table IV).

Discussion

The genetic diversity of M. tuberculosis genome and hence their population structure, is strongly linked to geography reinforcing the importance of localized effort to control tuberculosis. Utilizing these data for the clinical benefit of individual patients remains a challenge. Epidemiological studies are important in the surveillance of the disease to define its origin and spread in the community and for effective control and prevention. In this study, we have tried to define the genetic structure of the population of circulating M. tuberculosis isolates in and around Varanasi, north India. When the spoligotypes of these isolates were compared with those in the international spoligotype database of the Institute Pasteur de Guadalupe, it was found that 21 isolates were not identified in the SITVIT2 database. Of these 21 orphan isolates, only 8 cases were pan susceptible while the remaining 13 (61.90%) isolates corresponded to MDR-TB. This observation indicates the need of conducting multicenter studies to pinpoint all the prevalent M. tuberculosis spoligotypes in the Indian subcontinent. The remaining 83 isolates were distributed in 38 shared types or SITs. Twenty six (31.33%) isolates presented unique SITs, while the remaining 57 were clustered in 12 groups of 2 to 21 isolates each. TB is a leading health problem in India, still our knowledge regarding the circulating strains of M. tuberculosis is limited. Studies done so far, suggest Central Asian family (CAS) to be the major clade in the north whereas East African Indian (EAI) predominates in the southern part of India12021. In general, Beijing genogroup is present in low percentage throughout the country20212223. The emergence of this family continues to pose a serious threat to TB control due to its high virulence and frequent association with multi-drug resistance. Beijing family is highly prevalent throughout Asia and Eurasia24, with a reported prevalence of approximately 3–11 per cent in India202125. In our region spoligotype patterns showed that Beijing clade was the largest clade (22.11%) corresponded by SIT1, SIT250 and SIT621 and this was quite higher than the above reported frequencies. In the international database, SIT1 contains 10.7 per cent of the isolates reported. Association of Beijing strain with MDR-TB has been noted in studies carried out in United States, Estonia, Vietnam and Russia262728 but others have not found any association between Beijing family and drug resistance2930. However, in the present study the association of Beijing strain with MDR-TB was observed at a high frequency (29.41%), accounting for nearly one third of the MDR-TB isolates. While another five of 23 Beijing genotypes were pan susceptible, two isolates were resistant to INH, STR and EMB and one isolate was resistant to INH only. Of the 23 patients harbouring Beijing genotypes, 13 were previously treated and 10 of them were having MDR-TB Beijing genotypes. Three of them were HIV seropositive with non-MDR-TB Beijing genotypes. A study by Almeida et al31 showed agreement with our finding and found 35 per cent of the Beijing genotype among MDR-TB isolates recovered in and around Mumbai, India. The authors did not report any pan susceptible Beijing isolate in their study sample. In another study from Kanpur, north India, among eight Beijing isolates, six (75%) were MDR-TB, one isolate was resistant to RIF, STR and kanamycin (KAN) and one isolate was sensitive to all six drugs tested12. However, the results of the present study regarding Beijing genotype should not be overinterpreted, as our samples were obtained from a tertiary care center, and sampling bias cannot be ruled out. Also, the fact that many of the Beijing strains were from patients with acquired resistance strongly suggested that a susceptible population could be present in our setting. In our study, the second largest clade was CAS family (21.15%) represented by SIT24, SIT26, SIT288, SIT429, SIT599, SIT794, SIT954, SIT1327, SIT1346 and SIT2392 and among these the most predominant spoligotype was SIT26 (16.35%). Studies in north India showed that CAS1-DELHI strain was prevalent in 22-37% of isolates12202123 whereas it was found at a lower frequency (7.4%) in a study from Mumbai22 and represents only 1.7 per cent of strains in the SITVIT2 database. SIT26 represents 1.63 per cent of isolates in the updated SITVIT2 database and has been reported from 39 countries in varying numbers, with maximum number of isolates from Asian countries. A study from Pakistan also showed CAS1-DELHI type (39%) as the dominant isolate32. SIT26 is limited mainly to the Middle East and to Central Asia. It has also been found in regions in which frequent migration to and from the Indian subcontinent occurs, e.g., Saudi Arabia, Kenya, South Africa, Malaysia, Myanmar, Australia, USA and parts of Europe. The third-largest spoligotype found in our study was EAI family lineages (17.31%) with predominance of EAI3_IND (7.69%). It has also been found to be a major spoligotype in other studies from Delhi2223. Further, 13 (12.5%) isolates belonged to T super family (prototype T, T1 and T3), a widespread yet poorly defined super family, needing better markers for proper characterizations27 among which 11 (10.58%) belonged to T1 prototype. Mathuria et al24 found 9.6 per cent prevalence of T1 prototype of T super family. Predominant spoligotypes, i.e., SIT1, 11, 26, 53, 288 and 954, within this study were also most prevalent in North America and United States. The SIT (SIT3366, n=3) which was newly created within the study was also found predominantly in South Asia. Among these three patients with SIT3366 isolate, two were from Jaunpur and one was from Varanasi region of north India. One of these three patients had HIV seropositivity and another one had previous treatment history. Binary logistic regression was applied to analyze the “clustering” of M. tuberculosis isolates in association with patients’ demographics, clinical profiles and the bacteriologic features. The isolates were more likely to be clustered in HIV seropositive patients, and the percentage of clustering was significantly higher in smear-negative TB patients as compared to smear-positive patients. However, most of these smear-negative specimens were found to be culture positive. The overall numbers of clustered isolates were also high among smear-positive patients, which may extend the transmission period of the pathogen between hosts by infecting more persons around an index case. Also, the presence of HIV is known to increase the risk of rapid progression from infection to disease, a fact that may indirectly increase TB transmission rates in the community14. Early TB detection and efficient treatment are necessary steps to control this infectious disease; hence the information regarding the transmission patterns of drug-resistant M. tuberculosis isolates is a prerequisite in decision-making for TB control. High TB burden regions3435 are known to harbour a higher prevalence of the katG315Thr mutation in INH resistant isolates compared to low TB burden areas36. Among drug-resistant TB patients, a considerably high clustering proportion of katG315Thr allele was observed in our study. This allele was associated with MDR-TB as reported elsewhere36, and might serve as a surrogate marker to identify the recent transmission of MDR-TB and INH resistant isolates in studied areas. TB epidemic in Varanasi, north India is caused by a wide diversity of spoligotypes with predominance of four genotype lineages: Beijing, CAS, EAI and T. The Beijing genotype was the most frequent single spoligotype and strongly associated with MDR-TB isolates in Varanasi, North India. We showed that the bulk of ongoing transmission with MDR-TB strains in Varanasi, northern India is linked to Beijing genotype followed by the CAS1_Delhi lineage. These findings have important implications for the control and prevention of tuberculosis. Larger studies with representative sampling are needed to elucidate the actual status and role of these genotypes in the dissemination and transmission of TB in Northern India as well as elsewhere in India. This study represents a baseline study of the M. tuberculosis population structure in Eastern Uttar Pradesh, and may serve as an impetus for future molecular epidemiological studies in north India, and help comprehend the global tubercle bacilli genotypic diversity. Additional studies using 2nd-line typing using MIRU-VNTRs over an extended period of time and an exhaustive recruitment of patients would be beneficial to fully understand the epidemiology of TB and its transmission dynamics in this region.
  34 in total

1.  High incidence of the Beijing genotype among multidrug-resistant isolates of Mycobacterium tuberculosis in a tertiary care center in Mumbai, India.

Authors:  Deepak Almeida; Camilla Rodrigues; Tester F Ashavaid; Ajit Lalvani; Zarir F Udwadia; Ajita Mehta
Journal:  Clin Infect Dis       Date:  2005-02-18       Impact factor: 9.079

2.  Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology.

Authors:  J D van Embden; M D Cave; J T Crawford; J W Dale; K D Eisenach; B Gicquel; P Hermans; C Martin; R McAdam; T M Shinnick
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

3.  Spoligotyping of Mycobacterium tuberculosis isolates from patients with pulmonary tuberculosis in Mumbai, India.

Authors:  Savita Kulkarni; Christophe Sola; Ingrid Filliol; Nalin Rastogi; Gururaj Kadival
Journal:  Res Microbiol       Date:  2005-02-07       Impact factor: 3.992

4.  Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology.

Authors:  J Kamerbeek; L Schouls; A Kolk; M van Agterveld; D van Soolingen; S Kuijper; A Bunschoten; H Molhuizen; R Shaw; M Goyal; J van Embden
Journal:  J Clin Microbiol       Date:  1997-04       Impact factor: 5.948

5.  Spoligotyping of Mycobacterium tuberculosis isolates from Pakistan reveals predominance of Central Asian Strain 1 and Beijing isolates.

Authors:  Zahra Hasan; Mahnaz Tanveer; Akbar Kanji; Qaiser Hasan; Solomon Ghebremichael; Rumina Hasan
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

6.  Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family.

Authors:  P J Bifani; B B Plikaytis; V Kapur; K Stockbauer; X Pan; M L Lutfey; S L Moghazeh; W Eisner; T M Daniel; M H Kaplan; J T Crawford; J M Musser; B N Kreiswirth
Journal:  JAMA       Date:  1996-02-14       Impact factor: 56.272

7.  MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE.

Authors:  G CANETTI; S FROMAN; J GROSSET; P HAUDUROY; M LANGEROVA; H T MAHLER; G MEISSNER; D A MITCHISON; L SULA
Journal:  Bull World Health Organ       Date:  1963       Impact factor: 9.408

8.  Multiplex PCR assay specific for the multidrug-resistant strain W of Mycobacterium tuberculosis.

Authors:  B B Plikaytis; J L Marden; J T Crawford; C L Woodley; W R Butler; T M Shinnick
Journal:  J Clin Microbiol       Date:  1994-06       Impact factor: 5.948

9.  Mycobacterium tuberculosis Beijing genotype, northern Malawi.

Authors:  Judith R Glynn; Amelia C Crampin; Hamidou Traore; Malcolm D Yates; Frank D Mwaungulu; Bagrey M Ngwira; Steven D Chaguluka; Donex T Mwafulirwa; Sian Floyd; Caroline Murphy; Francis A Drobniewski; Paul E M Fine
Journal:  Emerg Infect Dis       Date:  2005-01       Impact factor: 6.883

10.  Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology.

Authors:  Karine Brudey; Jeffrey R Driscoll; Leen Rigouts; Wolfgang M Prodinger; Andrea Gori; Sahal A Al-Hajoj; Caroline Allix; Liselotte Aristimuño; Jyoti Arora; Viesturs Baumanis; Lothar Binder; Patricia Cafrune; Angel Cataldi; Soonfatt Cheong; Roland Diel; Christopher Ellermeier; Jason T Evans; Maryse Fauville-Dufaux; Séverine Ferdinand; Dario Garcia de Viedma; Carlo Garzelli; Lidia Gazzola; Harrison M Gomes; M Cristina Guttierez; Peter M Hawkey; Paul D van Helden; Gurujaj V Kadival; Barry N Kreiswirth; Kristin Kremer; Milan Kubin; Savita P Kulkarni; Benjamin Liens; Troels Lillebaek; Minh Ly Ho; Carlos Martin; Christian Martin; Igor Mokrousov; Olga Narvskaïa; Yun Fong Ngeow; Ludmilla Naumann; Stefan Niemann; Ida Parwati; Zeaur Rahim; Voahangy Rasolofo-Razanamparany; Tiana Rasolonavalona; M Lucia Rossetti; Sabine Rüsch-Gerdes; Anna Sajduda; Sofia Samper; Igor G Shemyakin; Urvashi B Singh; Akos Somoskovi; Robin A Skuce; Dick van Soolingen; Elisabeth M Streicher; Philip N Suffys; Enrico Tortoli; Tatjana Tracevska; Véronique Vincent; Tommie C Victor; Robin M Warren; Sook Fan Yap; Khadiza Zaman; Françoise Portaels; Nalin Rastogi; Christophe Sola
Journal:  BMC Microbiol       Date:  2006-03-06       Impact factor: 3.605

View more
  14 in total

1.  Systematic Review of Mutations Associated with Isoniazid Resistance Points to Continuing Evolution and Subsequent Evasion of Molecular Detection, and Potential for Emergence of Multidrug Resistance in Clinical Strains of Mycobacterium tuberculosis.

Authors:  Siavash J Valafar
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

2.  Genotypic diversity of Mycobacterium tuberculosis isolates from North-Central Indian population.

Authors:  Ravi Prakash; Rahul Gupta; Pragya Sharma; Sanjay Jain; Devendra Singh Chauhan; Vishwa Mohan Katoch; Pramod Kumar Tiwari
Journal:  Pathog Glob Health       Date:  2019-03-01       Impact factor: 2.894

3.  Mycobacterium tuberculosis strain lineage in mixed tribal population across India and Andaman Nicobar Island.

Authors:  Azger Dusthackeer; Ashok Kumar; Sucharitha Kannappan Mohanvel; B Mahizhaveni; S Shivakumar; S Raghavi; S Azhagendran; S Vetrivel; Vikas Gangadhar Rao; Rajiv Yadav; Vijayachari Paluru; Anil Jacob Purthy; Tahziba Hussain; Vivek Kashyap; K Rekha Devi; Anil Kumar Indira Krishnan; Praveen Anand; Pradeep Das; Avi Kumar Bansal; Madhuchhanda Das; Harpreet Kaur; D Raghunath; Rajesh Mondal; Beena E Thomas
Journal:  World J Microbiol Biotechnol       Date:  2021-10-12       Impact factor: 3.312

4.  Drug-resistant tuberculosis: an experience from Qatar.

Authors:  Maisa Ali; Faraj Howady; Waqar Munir; Hanfa Karim; Zubaida Al-Suwaidi; Muna Al-Maslamani; Abdullatif Alkhal; Nada Elmaki; Hisham Ziglam
Journal:  Libyan J Med       Date:  2020-12       Impact factor: 1.657

5.  Mycobacterium tuberculosis Whole Genome Sequences From Southern India Suggest Novel Resistance Mechanisms and the Need for Region-Specific Diagnostics.

Authors:  Abigail L Manson; Thomas Abeel; James E Galagan; Jagadish Chandrabose Sundaramurthi; Alex Salazar; Thies Gehrmann; Siva Kumar Shanmugam; Kannan Palaniyandi; Sujatha Narayanan; Soumya Swaminathan; Ashlee M Earl
Journal:  Clin Infect Dis       Date:  2017-06-01       Impact factor: 9.079

6.  Genetic diversity of Mycobacterium tuberculosis in south coastal Karnataka, India, using spoligotyping.

Authors:  Kiran Chawla; Ajay Kumar; Vishnu Prasad Shenoy; Devendra Singh Chauhan; Pragya Sharma
Journal:  Indian J Med Res       Date:  2018-03       Impact factor: 2.375

7.  Comparative Evaluation of Several Gene Targets for Designing a Multiplex-PCR for an Early Diagnosis of Extrapulmonary Tuberculosis.

Authors:  Ankush Raj; Netrapal Singh; Krishna B Gupta; Dhruva Chaudhary; Aparna Yadav; Anil Chaudhary; Kshitij Agarwal; Mandira Varma-Basil; Rajendra Prasad; Gopal K Khuller; Promod K Mehta
Journal:  Yonsei Med J       Date:  2016-01       Impact factor: 2.759

8.  Genetic Diversity of Mycobacterium tuberculosis Isolates from Assam, India: Dominance of Beijing Family and Discovery of Two New Clades Related to CAS1_Delhi and EAI Family Based on Spoligotyping and MIRU-VNTR Typing.

Authors:  Kangjam Rekha Devi; Rinchenla Bhutia; Shovonlal Bhowmick; Kaustab Mukherjee; Jagadish Mahanta; Kanwar Narain
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

9.  Molecular & genetic characteristics of Mycobacterium tuberculosis strains circulating in the southern part of West Siberia.

Authors:  Oksana Pasechnik; Maya Alexandrovna Dymova; Vladimir Leonidovich Stasenko; Aleksey Igorevich Blokh; Marina Petrovna Tatarintseva; Lyubov Pavlovna Kolesnikova; Maksim Leonidovich Filipenko
Journal:  Indian J Med Res       Date:  2017-07       Impact factor: 2.375

10.  The study on the association between Beijing genotype family and drug susceptibility phenotypes of Mycobacterium tuberculosis in Beijing.

Authors:  Yi Liu; Xiaoying Jiang; Wensheng Li; Xuxia Zhang; Wei Wang; Chuanyou Li
Journal:  Sci Rep       Date:  2017-11-08       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.